An observational study in Coronary Occlusion and Percutaneous Coronary Intervention, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 21 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by National Institute of Cardiology, Warsaw, Poland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to evaluate the safety, efficacy, and clinical outcomes of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) in patients treated in contemporary clinical practice in Poland.
The main questions it aims to answer are:
Patients undergoing CTO PCI as part of their standard medical care will be prospectively enrolled in a national, multicenter registry, with clinical, procedural, and follow-up data collected to evaluate real-world outcomes.
Coronary chronic total occlusions (CTO) are diagnosed in approximately 20% of patients undergoing invasive coronary angiography, and their presence is associated with significantly reduced quality of life and worse long-term prognosis compared with patients without a CTO. Successful CTO recanalization improves quality of life, regional and global left ventricular function, and reduces myocardial ischemia in most patients. Over the past decade, the success rate of percutaneous coronary intervention (PCI) for CTO has increased substantially, largely due to advances in dedicated equipment and specialized procedural techniques. Concurrently, there is a growing need to evaluate the safety and effectiveness of contemporary CTO PCI techniques in selected patient populations.
The aim of the POL-CTO registry is to expand current knowledge regarding the safety and efficacy of CTO PCI in the contemporary Polish population across a broad range of clinical scenarios. Specifically, the registry will examine the incidence and management of periprocedural complications, as well as the impact of post-procedural cardiac injury markers on clinical outcomes. Comparative analyses of PCI performed with versus without intravascular imaging, along with different treatment strategies (drug-coated balloon [DCB], drug-eluting stent [DES], or hybrid approaches), will be conducted. Additional objectives include evaluating the safety of PCI with mechanical circulatory support and predicting quality-of-life improvement using artificial intelligence-based analysis of baseline electrocardiograms. Finally, the study will focus on CTO PCI outcomes in high-risk subgroups, including patients with low ejection fraction, frailty syndrome, severe coronary calcification, diabetes, prior transcatheter aortic valve implantation, prior coronary artery bypass grafting, and in-stent CTO.
71 studies on the registry are indexed under Coronary Occlusion; 11 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 659 across 26 observational studies indexed under Coronary Occlusion.
Browse Coronary Occlusion studies →National Institute of Cardiology, Warsaw, Poland is the lead sponsor of 54 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients undergoing CTO PCI at participating centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Technical success
Achievement of Thrombolysis In Myocardial Infarction grade 3 flow in all ≥2.5-mm distal branches with \<30% residual stenosis.
Time frame: procedural (1 day)
Total procedure time
Total procedure time in minutes.
Time frame: procedural (1 day)
Fluoroscopy time
Fluoroscopy time in minutes.
Time frame: procedural (1 day)
Radiation dose
Total radiation dose in Gy and uGycm2.
Time frame: procedural (1 day)
Contrast volume
Total contrast volume in mL.
Time frame: procedural (1 day)
Number and type of procedural complications
Total number and specification of procedural complications (death, non-fatal myocardial infarction, cardiac tamponade requiring pericardiocentesis, coronary perforation, stroke, major bleeding according to Bleeding Academic Research Consortium).
Time frame: procedural (1 day)
Successful guidewire crossing through CTO
Rate of successful guidewire crossing through CTO.
Time frame: procedural (1 day)
Time of successful guidewire crossing
Time of successful guidewire crossing through CTO in minutes defined as the time from starting primary CTO PCI strategy to the time of successful CTO recanalization using any technique.
Time frame: procedural (1 day)
Target lesion failure
Total number of cardiac death, target vessel-related myocardial infarction or clinically-driven target lesion revascularization
Time frame: in-hospital (2-5 days)
Target lesion failure
otal number of cardiac death, target vessel-related myocardial infarction or clinically-driven target lesion revascularization
Time frame: 1 year
Death
Any death
Time frame: 1 year
Started May 2025 (actual). Primary completion is estimated for May 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cardiology, Warsaw, Poland